Clofibric acid or diethylmaleate supplemented diet decrease blood pressure in DOCA-salt treated male Sprague Dawley rats--relation with liver antioxidant status.
The effects of 8-week diethylmaleate (DEM) and clofibric acid (CFA) supplemented diet on blood pressure, body and liver weights, liver antioxidant status and nitric oxide synthase (NOS) activity were investigated in 8-week DOCA-salt treated and untreated Sprague-Dawley male rats. It appeared that DEM and particularly CFA treatments were associated with a significant decrease in blood pressure in DOCA-salt treated rats, and an accentuation of the decreases in body weights in both diet supplemented groups. This was not associated with increases in NO production in the liver. In contrast, hepatic lipid peroxidation was significantly decreased in both DOCA-salt treated and untreated groups on DEM and particularly on CFA supplemented diet. The protective effects of CFA and DEM against hepatic cellular damage could be involved in the decreases in blood pressure in DOCA-salt treated rats, where CFA was more efficient than DEM. In CFA supplemented groups, there was a strong increase in hepatic superoxide dismutase (SOD), glutathione-peroxidase (GSH-Px), and catalase (CAT) activities and in DEM supplemented groups, increases in SOD and CAT activities and in GSH levels were observed. Our data suggest that normalization of blood pressure in DOCA-salt treated rats by CFA was due to an enhancement of the half-life of NO while DEM increased its availability.
Nicod
L
L
Laboratoire de Biologie Cellulaire, UFR Médecine-Pharmacie, Besançon, France.
Rodriguez
S
S
Jacqueson
A
A
Viollon-Abadie
C
C
Berthelot
A
A
Richert
L
L
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D002374:Catalase / Q000378:metabolism; D002995:Clofibric Acid / Q000008:administration & dosage / Q000494:pharmacology*; D003900:Desoxycorticosterone / Q000008:administration & dosage; D004032:Diet; D005978:Glutathione / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D015227:Lipid Peroxidation; D008099:Liver / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D008297:Male; D008298:Maleates / Q000494:pharmacology*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D009929:Organ Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D012965:Sodium Chloride / Q000008:administration & dosage; D013482:Superoxide Dismutase / Q000378:metabolism
D000960:Hypolipidemic Agents; D008298:Maleates; D003900:Desoxycorticosterone; D012965:Sodium Chloride; D002995:Clofibric Acid; D002374:Catalase; D019001:Nitric Oxide Synthase; D013482:Superoxide Dismutase; C014476:diethyl maleate; D005978:Glutathione